• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Tranexamic acid decreases postoperative bleeding in non-cardiac surgery patients

byAndrew LeeandKiera Liblik
June 18, 2022
in Cardiology, Surgery
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Compared to placebo, tranexamic acid (TXA) use in noncardiac surgery patients reduced the risk of bleeding 30 days postoperatively in non-cardiac surgery patients.

2. TXA use was associated with a slightly elevated risk of cardiovascular complications 30 days post-operatively compared to placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Perioperative bleeding is a common complication of non-cardiac surgery associated with an increased risk of mortality. TXA has been previously demonstrated to decrease bleeding in patients undergoing cesarean sections or cardiac surgery. However, it is unclear whether TXA reduces risk of postoperative bleeding in non-cardiac surgery patients. This randomized control trial compared postoperative bleeding outcomes in non-cardiac patients administered either a placebo control or TXA immediately before and after surgery. Additionally, cardiovascular risk associated with TXA use in this population was assessed. At 30-days postoperatively, bleeding outcomes were significantly lower in the TXA group compared to the placebo control. Notably, TXA was associated with a small but significant increase in risk of adverse cardiovascular outcomes during the follow-up period. A major limitation of this trial is that it was interrupted prematurely due to fiscal deficit. However, over 95% of the originally planned sample size was successfully enrolled.

Click to read the study in NEJM

Click to read an accompanying editorial in NEJM

Relevant Reading: Association between complications and death within 30 days after non-cardiac surgery

RELATED REPORTS

Tranexamic acid is unlikely to induce signs suggestive of cerebral ischemia in the treatment of acute intracerebral hemorrhage: TICH-2 study

Prophylactic tranexamic acid prevents significant blood loss after cesarean delivery

Early, short-term tranexamic acid does not improve clinical outcomes at 6 months in patients with subarachnoid hemorrhage 

In-Depth [randomized control trial]: The Perioperative Ischemic Evaluation–3 (POISE-3) randomized control trial compared the postoperative outcomes of non-cardiac patients receiving either one gram of intravenous TXA (n=4,757) or a placebo control (n=4,778) perioperatively. The primary outcome was composite bleeding (life-threatening bleeding, major bleeding, or bleeding into a critical organ) 30 days postoperatively. The composite bleeding outcome occurred in 433 patients (9.1%) in the TXA group and in 561 patients (11.7%) in the placebo group (hazard ratio [HR], 0.76; 95% Confidence Interval [CI], 0.67 to 0.87). Further, bleeding independently associated with death occurred in 416 patients in the TXA group (8.7%) and in 514 patients in the placebo group (11.3%) during the follow-up period (HR, 0.76; 95% CI, 0.67 to 0.87). TXA safety was evaluated using a composite cardiovascular outcome (myocardial injury after noncardiac surgery, non-hemorrhagic stroke, peripheral arterial thrombosis, or symptomatic proximal venous thromboembolism) within the 30-day follow-up period. This occurred in 649 patients (14.2%) in the TXA group and 639 patients (13.9%) in the placebo group (HR, 1.02; 95% CI, 0.92 to 1.14).  Overall, this study demonstrated that in patients undergoing non-cardiac surgery, the incidence of life-threatening bleeding, major bleeding, and bleeding into a critical organ was significantly lower in those receiving TXA compared to placebo. Though, TXA may be associated with a slight increase in postoperative adverse cardiovascular events.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: bleedingnon-cardiac surgeryperioperativeTranexamic acid
Previous Post

Risankizumab induction therapy is effective for moderate-to-severe Crohn’s disease

Next Post

Viral meningitis can be differentiated from abusive head trauma with demographic, history, and clinical findings

RelatedReports

Intensive rehabilitation not superior to traditional therapy for arm function after stroke
Emergency

Tranexamic acid is unlikely to induce signs suggestive of cerebral ischemia in the treatment of acute intracerebral hemorrhage: TICH-2 study

March 22, 2022
No differences in pain between suture and staple C-Section closure
Emergency

Prophylactic tranexamic acid prevents significant blood loss after cesarean delivery

May 4, 2021
2 Minute Medicine Rewind June 1 – June 7, 2015
Emergency

Early, short-term tranexamic acid does not improve clinical outcomes at 6 months in patients with subarachnoid hemorrhage 

June 25, 2021
#VisualAbstract DIVERSITY trial: Dabigatran etexilate was non-inferior to standard of care in effectively treating acute venous thromboembolism (VTE) in children
StudyGraphics

#VisualAbstract DIVERSITY trial: Dabigatran etexilate was non-inferior to standard of care in effectively treating acute venous thromboembolism (VTE) in children

December 31, 2020
Next Post
Combined MRI and NIH stroke scores may predict stroke prognosis

Viral meningitis can be differentiated from abusive head trauma with demographic, history, and clinical findings

Quick Take: Association of Visual Impairment With Economic Development Among Chinese Schoolchildren

No therapies for computer vision syndrome with high certainty evidence in meta-analysis

Mediterranean diet linked to reduced diabetes risk in high risk cardiovascular patients

Sodium-glucose cotransporter 2 inhibitors reduce heart failure hospitalization in type 2 diabetes patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Hybrid immunity protects against infection with omicron variant of COVID-19
  • #VisualAbstract: Tirzepatide Once Weekly for the Treatment of Obesity
  • Wellness Check: Sleep
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.